聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎疗效观察

目的评价聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎的临床疗效。方法聚乙二醇干扰素α-2a（派罗欣）联合利巴韦林（800-1200mg／d）治疗58例慢性丙型肝炎患者，疗程48周，分别于治疗4、12、24和48周及治疗结束后24周评价疗效，并观察药物副作用。结果RVR：36例（62.1％）EVR：18例（31.0％），SLVR：3例（5.2％），ETVR54例（93.1％），SVR：52例（89.7％）；HCVRNA高水平组和低水平组之闻持续应答率分别为66.7％和50.0％，差异有统计学意义（P〈0.05）。结论在慢性丙型肝炎患者的治疗中SVR54（93.1％），HCV-RNA低水平组的疗效优于高水平组。

EFFICACY OF COMBINATION THERAPY WITH PEGYLATED- INTERFERON ALFA - 2A PLUS RIBA- VIRIN IN CHRONIC HEPATITIS C PATIENTS

Objective To observe the clinical effect of pegylated- interferon alfa- 2a plus ribavirin（800- 1 200mg/d） in treatment of chronic hepatitis C patients. Methods Totally 58 HCV patients were adminis- tered a 48 - week course by Peg- IFNα - 2a ＋ RBV. The HCV viral load was tested at treatment weeks 0 （baseline）,4,12,24,48 and drugs were withdrawed after week 24. Results The RVR, EVR, SLVR, ETVR and SVR were 62.1%, 34. 5%, 3.6%, 98.3% and 93.1% respectively in this study. Sustained viral response rates for the high HCV viral load group was 56. 3% and it was 80.8% for the low HCV viral load group, The SVR showed a significant difference between the two groups（P〈0.05）. Conclusions The effect of pegylated - interferon alfa - 2a plus ribavirin in treatment of chronic hepatitis C is satisfactorily （SVR 93.1%）. The low HCV viral load group respond better to Peg- IFNα-2a ＋ RBV therapy than the high HCV viral load group. Key words Hepatitis C virus; Pegylated- interferon alfα- 2a; Ribavirin; Combination therapy